Investor relations

In July 2022, the Norwegian Transparency act based on OECD guidelines entered into force.
The law states that companies should:

– Carry out human rights and decent working conditions due diligence in its own business and value chain

– Publicly account for its due diligence, including its procedures and identified risks

– Provide information upon request

Medistim has a company-wide approach to human rights due diligence which is integrated into our governance structure. A description of our implementation of the act and the main results of our risk based approach is presented in our Transparency Act report for 2023. Click below to read.

For further information, please send an inquiry to medistim@medistim.com